Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

antidote

Boehringer Ingelheim headquarters

Boehringer’s sales drop after ‘intense and challenging’ year

US operations hit hard by healthcare reforms and insurance consolidation

- PMLiVE

Quality in Care anticoagulation programme open for entry

PMGroup's QiC programme aims to recognise best practice in care in the UK

Boehringer Ingelheim headquarters

Boehringer signs renal disease research collaboration

Will work with Hydra Biosciences to identify small-molecule TRP inhibitors

- PMLiVE

IQWiG passes Boehringer lung cancer drug

Germany’s cost assessor says it can extend life in some patients, but benefit it ‘minor'

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

- PMLiVE

Boehringer to move psoriasis programme into phase III

Candidate outperformed J&J’s rival Stelara 

- PMLiVE

Boehringer steals lead among NOACs with Pradaxa antidote

Has filed reversal agent for European approval

- PMLiVE

Boehringer in breach over beer drinking, lederhosen presentation

German firm earns PMCPA’s wrath over ‘inappropriate’ conference speakers

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

Daiichi Sankyo logo

Daiichi’s novel anticoagulant Savaysa cleared in US

Approval comes more than three years after it was approved in Japan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links